FDA May Refuse Entry, Deny Applications for Canadian Drug Company Apotex
The Food and Drug Administration found violations of Current Good Manufacturing Practice regulations at two of Canadian pharmaceutical manufacturer Apotex’s facilities, and may withhold approval of new drug applications and refuse admission as a result, said FDA in a warning…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
letter. “The evidence suggests that Apotex has failed to implement adequate global and sustainable corrective and preventive actions, and that it continues to manufacture and distribute pharmaceutical product without upholding its legal obligation to comply with CGMP,” FDA said.